MAPT and Alzheimer disease: In a mouse model of AD, the improvement of pathological changes could be augmented by exogenous supplementation of TFEB (Polito et al., 2014), which was achieved by inducing autophagy and reducing tau via promoting lysosomal exocytosis (Xu et al., 2020).